Open AccessCarfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
Author(s) -
Español Ignacio,
Romera Marta,
GutiérrezMeca María Dolores,
García Maria del Carmen,
Tejedor Aurelia,
Martínez Antonio,
Ibáñez Jerónima,
De Arriba Felipe,
Minguela Alfredo,
Iturbe Teodoro,
López Maria Dolores
Publication year - 2017
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1015
Subject(s) - medicine , dexamethasone , carfilzomib , multiple myeloma , appropriateness criteria , radiology , intensive care medicine , dermatology , lenalidomide
Key Clinical Message The dismal outcome of pleuropericardial extramedullary multiple myeloma ( EMM ) reflects both the selection of resistant disease and absence of useful drugs. Carfilzomib and dexamethasone should be explored in advanced EMM patients, even for bortezomib‐resistant patients, as may provide much longer overall survival than previously reported treatments.